Revance price target raised to $38 from $35 at Barclays. RVNC Barclays analyst Balaji Prasad raised the firm's price target on Revance to $38 from $35 and keeps an Overweight rating on the shares. The analyst expects to see signs of a broader recovery in Q3 for the U.S. Specialty Pharmaceuticals companies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.